Literature DB >> 28098401

Antibiotic resistance of Helicobacter pylori in Chinese children: A multicenter retrospective study over 7 years.

Lan Li1, Yini Ke1, Chaohui Yu1, Guogang Li2, Ningmin Yang3, Jianzhong Zhang4,5, Youming Li1.   

Abstract

BACKGROUND: To determine the prevalence of resistance to metronidazole, clarithromycin, levofloxacin, amoxicillin, and furazolidone in Helicobacter pylori isolated from Chinese children.
MATERIALS AND METHODS: This multicenter retrospective study was conducted from January 2009 to December 2015. A total of 1746 isolates of H. pylori were collected from nine areas of Zhejiang province in the southeast coastal region of China. H. pylori strains were examined for antibiotics susceptibility by agar dilution method.
RESULTS: The resistance rates were 75.20% for metronidazole, 16.38% for clarithromycin, 6.70% for levofloxacin, 0.06% for amoxicillin, and 0.06% for furazolidone. The pattern of H. pylori antibiotic resistance demonstrated no significant changes in the rates of resistance to clarithromycin, amoxicillin, furazolidone, and metronidazole over 7 years. A significant trend of increasing resistance to metronidazole was observed as children aged, but a downward trend in clarithromycin resistance was observed as children aged. No difference in the resistance to other antibiotics was observed among different age groups. Also, there was no significant difference between male and female subjects in rates of resistance to these five types of antibiotics. The predominant dual resistance to metronidazole and clarithromycin was presented in 10.65% of the isolates.
CONCLUSIONS: The resistance rates of H. pylori in children from southeast coastal region of China were very high to metronidazole, moderate to clarithromycin and levofloxacin, and low to amoxicillin and furazolidone. It is important to continue monitoring the resistance profiles of H. pylori isolated in this region.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Helicobacter pylorizzm321990; antibiotic resistance; children

Mesh:

Substances:

Year:  2017        PMID: 28098401     DOI: 10.1111/hel.12373

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  6 in total

1.  Analysis of culturable microbiota present in the stomach of children with gastric symptoms.

Authors:  Changcheng Guo; Fang Liu; Li Zhu; Fangcao Wu; Guzhen Cui; Yan Xiong; Qiong Wang; Lin Yin; Caixia Wang; Huan Wang; Xiaojuan Wu; Zhengrong Zhang; Zhenghong Chen
Journal:  Braz J Microbiol       Date:  2018-12-19       Impact factor: 2.476

2.  Phenotype and Molecular Detection of Clarithromycin and Levofloxacin Resistance in Helicobacter pylori Clinical Isolates in Beijing.

Authors:  Chong-Hou Lok; Dong Zhu; Jia Wang; Yu-Tang Ren; Xuan Jiang; Shu-Jun Li; Xiu-Ying Zhao
Journal:  Infect Drug Resist       Date:  2020-07-06       Impact factor: 4.003

3.  Correlation Analysis Among Genotype Resistance, Phenotype Resistance and Eradication Effect of Helicobacter pylori.

Authors:  Rongli Cui; Zhiqiang Song; Baojun Suo; Xueli Tian; Yan Xue; Lingmei Meng; Zhanyue Niu; Zhu Jin; Hejun Zhang; Liya Zhou
Journal:  Infect Drug Resist       Date:  2021-05-11       Impact factor: 4.003

4.  Antibiotic Resistance of Helicobacter pylori Isolated from Patients after Partial Gastrectomy: A Retrospective Study.

Authors:  Lan Li; Weihua Zhou; Hongzhang Li; Chaohui Yu; Tianlian Yan; Ningmin Yang; You-Ming Li
Journal:  Turk J Gastroenterol       Date:  2021-12       Impact factor: 1.555

5.  The effect of virulence genotypes of Helicobacter pylori on eradication therapy in children.

Authors:  Shuang-Hong Zhang; Xuan Zhu; Bi-Min Li; Hong Li
Journal:  Saudi J Gastroenterol       Date:  2018 Jul-Aug       Impact factor: 2.485

6.  Ninety-four thousand-case retrospective study on antibacterial drug resistance of Helicobacter pylori.

Authors:  Yu Zhang; Fei Meng; Jie Jin; Jun Wang; Bin-Bin Gu; Jin-Bang Peng; Li-Ping Ye
Journal:  World J Clin Cases       Date:  2021-12-16       Impact factor: 1.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.